Europe Vaccine Adjuvants Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$462.8

Forecast, 2030 (US$M)

$526.0

CAGR, 2024 - 2030

1.8%

Report Coverage

Europe

Europe vaccine adjuvants market, 2018-2030 (US$M)

Related Markets

Global Vaccine Adjuvants Industry

North America Vaccine Adjuvants Market Outlook

Asia Pacific Vaccine Adjuvants Market Outlook

Latin America Vaccine Adjuvants Market Outlook

MEA Vaccine Adjuvants Market Outlook

Europe vaccine adjuvants market highlights

The Europe vaccine adjuvants market generated a revenue of USD 462.8 million in 2023.
The market is expected to grow at a CAGR of 1.8% from 2024 to 2030.
In terms of segment, cancer was the largest revenue generating end use in 2023.
Cancer is the most lucrative end use segment registering the fastest growth during the forecast period.

Europe data book summary

Market revenue in 2023	USD 462.8 million
Market revenue in 2030	USD 526.0 million
Growth rate	1.8% (CAGR from 2023 to 2030)
Largest segment	Cancer
Fastest growing segment	Cancer
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Cancer
Key market players worldwide	GlaxoSmithKline, Novavax Inc, Adjuvance Technologies, Associated British Foods PLC, CSL Ltd, InvivoGen, Agenus Inc, Brenntag Biosector

Other key industry trends

In terms of revenue, Europe region accounted for 27.9% of the global vaccine adjuvants market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
MEA is the fastest growing regional market and is projected to reach USD 90.6 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Vaccine Adjuvants Market Scope

Vaccine adjuvants market segmentation & scope

End Use

Infectious disease

Cancer

Others

Regions

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Countries

U.S.

Canada

Denmark

Germany

France

Italy

Norway

Spain

Sweden

Mexico

Brazil

Argentina

Kuwait

Saudi Arabia

South Africa

UAE

Thailand

South Korea

Australia

China

India

Japan

Vaccine Adjuvants Market Companies

Name	Profile	# Employees	HQ	Website

Europe vaccine adjuvants market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine adjuvants market will help companies and investors design strategic landscapes.

Cancer was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Europe vaccine adjuvants market based on cancer covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to Europe vaccine adjuvants market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe vaccine adjuvants market databook

Our clientele includes a mix of vaccine adjuvants market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe vaccine adjuvants market, including forecasts for subscribers. This continent databook contains high-level insights into Europe vaccine adjuvants market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list